Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.

AIMS To evaluate whether HD1916, a chemically synthesised semaglutide, is therapeutically equivalent to the reference product semaglutide (Wegovy) in body weight reduction among Chinese adults with obesity without diabetes. MATERIALS AND METHODS This multicenter, randomised, open-label, active-controlled Phase III tr...

Lei-Li Gao, Yu-Jin Ma, Qiu-Mei Zhang et al. · 0 citations
Oct 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

BACKGROUND For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational gluc...

Sean Wharton, C. L. le Roux, E. Startseva et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.